We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Management of Cardiovascular Risk Factors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00848380
Recruitment Status : Completed
First Posted : February 20, 2009
Last Update Posted : November 16, 2010
Sponsor:
Information provided by:
AstraZeneca

Brief Summary:
This practical experience should report a retrospective collection of data regarding cardiovascular risk factors of cardiovascular diseases. The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia

Condition or disease
Cardiovascular Risk Factors Cardiovascular Diseases

Study Type : Observational
Actual Enrollment : 1492 participants
Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Management of Cardiovascular Risk Factors
Study Start Date : February 2009
Primary Completion Date : December 2009
Study Completion Date : December 2009

Group/Cohort
1
Patients with hypertension and hyperlipidemia and other CV risk factors



Primary Outcome Measures :
  1. The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia. [ Time Frame: Inclusion visit, 6 to 9 months before inclusion visit and / or 12 to 15 months before inclusion visit ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients with hypertension and hyperlipidemia and other CV risk factors
Criteria

Inclusion Criteria:

  • Patients received a anti-hypertension treatment in addition to cholesterol lowering treatment during the observation period
  • Patients received a cholesterol lowering treatment in addition to hypertension treatment during the observation period
  • Patients received during the observation time new cholesterol lowering and hypertension treatment

Exclusion Criteria:

  • Patients received during the observation time only cholesterol lowering or only anti-hypertension treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00848380


Locations
Switzerland
Research Site
Frick, AG, Switzerland
Research Site
Neuenhof, AG, Switzerland
Research Site
Thun, BE, Switzerland
Research Site
Wynigen, BE, Switzerland
Research Site
Riehen, BS, Switzerland
Research Site
Geneve, GE, Switzerland
Research Site
Le Lignon, GE, Switzerland
Research Site
Meyrin, GE, Switzerland
Research Site
Andeer, GR, Switzerland
Research Site
Ilanz, GR, Switzerland
Research Site
Rorschach, SG, Switzerland
Research Site
St. Gallen, SG, Switzerland
Research Site
Gerlafingen, SO, Switzerland
Research Site
Lohn SO, SO, Switzerland
Research Site
Zuchwil, SO, Switzerland
Research Site
Schwyz, SZ, Switzerland
Research Site
Arbedo, TI, Switzerland
Research Site
Bellinzona, TI, Switzerland
Research Site
Claro, TI, Switzerland
Research Site
Coldrerio, TI, Switzerland
Research Site
Locarno, TI, Switzerland
Research Site
Lugano, TI, Switzerland
Research Site
Muralto, TI, Switzerland
Research Site
Bassins, VD, Switzerland
Research Site
Gland, VD, Switzerland
Research Site
Lausanne, VD, Switzerland
Research Site
Montreux, VD, Switzerland
Research Site
Nyon, VD, Switzerland
Research Site
Zug, ZG, Switzerland
Research Site
Affoltern am Albis, ZH, Switzerland
Research Site
Feldmeilen, ZH, Switzerland
Research Site
Herrliberg, ZH, Switzerland
Research Site
Langnau am Albis, ZH, Switzerland
Research Site
Richterswil, ZH, Switzerland
Research Site
Ruti ZH, ZH, Switzerland
Research Site
Zurich, ZH, Switzerland
Sponsors and Collaborators
AstraZeneca

Responsible Party: Dr. Dirk Schneider , Medical Affairs & Regulatory Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00848380     History of Changes
Other Study ID Numbers: NIS-CCH-DUM-2008/2
First Posted: February 20, 2009    Key Record Dates
Last Update Posted: November 16, 2010
Last Verified: November 2010

Keywords provided by AstraZeneca:
Hypertension
hyperlipidemia

Additional relevant MeSH terms:
Cardiovascular Diseases